# Clarivate LS&H sale: what GenAI means for pharma intelligence businesses

> Clarivate is selling its LS&H division — $390M in revenue, down 7% YoY, stock at $1.69. Decision Resources and Cortellis defined pharma intelligence for decades. GenAI-native platforms are now structuring, querying, and synthesizing across the same data at a fraction of the cost. When organized access to information is your moat, and AI organizes information better than you, that’s not a strategy problem. That’s an existential one.

URL: https://www.ch-healthtech.com/insights/clarivate-putting-its-life-sciences-healthcare-business-block
Markdown: https://www.ch-healthtech.com/insights/clarivate-putting-its-life-sciences-healthcare-business-block.md
Published: 2026-02-26
Updated: 2026-05-06
Author: Christian Hein
Tags: technology/artificial-intelligence, technology/generative-ai, industry/large-pharma, function/business-intelligence, function/strategic-planning, function/innovation-management

---


## TL;DR

Clarivate is putting its Life Sciences & Healthcare business on the block. The LS&H division did $390M last year, down 7% YoY, stock at $1.69. Morgan Stanley hired to find a buyer. Decision Resources was my go-to source of market intelligence at Amgen for years — well researched, well structured, worth every dollar. That entire model is under pressure. In my advisory work, dozens of founders have approached me with GenAI-enabled life science intelligence platforms; many are getting strong early traction, with pharma teams replacing legacy subscriptions entirely. When organized access to information is your moat, and AI learns to organize information better than you, that’s not a strategy problem. That’s an existential one. Different business model. Different winners.

Clarivate is putting its Life Sciences & Healthcare business on the block.

The LS&H division did $390M in revenue last year. Down 7% year over year. Stock at $1.69. Morgan Stanley hired to find a buyer.

But here’s what pharma leaders should be paying attention to.

Decision Resources (now part of the Clarivate suite) was my go-to source of market intelligence for years. Well researched, well structured, and worth every dollar of those six-figure licenses. I ran competitive intelligence, business planning, and BD at Amgen for several years and tools like DRG and Cortellis were the backbone of strategic decision-making.

That entire model is under pressure.

In my advisory work, I’ve had dozens of founders approach me with their version of GenAI-enabled life science intelligence platforms. What strikes me: many of them are getting really good early traction. Pharma teams are piloting these tools alongside their legacy subscriptions, and in some cases replacing them entirely.

For decades, companies like Clarivate, IQVIA, and Citeline built their moats around curated databases and structured intelligence. Pharma paid because there was no better way to make sense of fragmented biomedical data.
That moat is rapidly evaporating.

GenAI-native platforms can now structure, query, synthesize, and reason across scientific literature, clinical trial data, patent filings, and regulatory databases at a fraction of the cost.

When your competitive advantage is organized access to information, and AI learns to organize information better than you, that is not a strategy problem. That is an existential one.

Clarivate’s CEO said “97% of our revenue comes from proprietary assets.” But proprietary curation loses its premium when GenAI can do it faster, cheaper, and with broader reach.

This pattern will repeat across every knowledge-heavy vertical in healthcare. Regulatory intelligence. Commercial analytics. Clinical trial design.

The value is shifting from structured data to AI-driven insight generation.
Different business model. Different winners.

Question for pharma teams: which of your “intelligence subscriptions” are actually buying proprietary data, and which are really just buying an interface?

## Key takeaways

- Clarivate’s LS&H sale ($390M revenue, -7% YoY, stock at $1.69) is a structural signal, not just a corporate restructuring story.
- Decision Resources, DRG, and Cortellis defined pharma strategic intelligence for decades. That model is now under real pressure.
- Founders pitching GenAI-enabled intelligence platforms are getting strong early traction. Pharma teams are piloting them and, in some cases, replacing legacy subscriptions entirely.
- The moat was always curated access to fragmented biomedical data. GenAI structures, queries, synthesizes, and reasons across that data at a fraction of the cost.
- Proprietary curation loses its premium when GenAI does it faster, cheaper, and with broader reach. Clarivate’s “97% proprietary” framing made sense in a different world.
- The pattern will repeat across regulatory intelligence, commercial analytics, and clinical trial design. Any knowledge-heavy vertical in healthcare faces the same shift.
- The right question for pharma teams: which intelligence subscriptions buy proprietary data, and which just buy an interface?